china partner

HealthLinx Limited
ABN 88 098 640 352
576 Swan Street Richmond VIC 3121
Telephone: +61 3 9208 4200 I Facsimile: +61 3 9208 4201
www.healthlinx.com.au
China partner appointed for OvPlex�ovarian cancer diagnostic study
CytogenDx confirmed as partner for Chinese market
9 September 2011, Melbourne, Australia: HealthLinx Limited (ASX:HTX) has executed research agreements
with CytogenDx Co Ltd of China to begin a 350 patient academic study as the first step to launch the OvPlex�
ovarian cancer diagnostic in China.
The study will be conducted by Principal Investigator Dr Fei Xu of Wuxi Maternal and Children�s Hospital with
the aim to validate OvPlex� in the Chinese population. It will involve the recruitment of 350 patients from the
Wuxi and Shanghai districts. Upon a successful result the parties will then proceed with an SFDA approval
pathway to have OvPlex� registered for sale in China.
HealthLinx and CytogenDX will co-fund the study which will take 9-12 months to complete and is seen as the
precursor to obtaining SFDA approvals.
�China is potentially a huge market for OvPlex� so the commencement of the study is excellent news for the
company and its shareholders,� said HealthLinx managing director Nick Gatsios. �CytogenDX is a highly
respected healthcare company in the Chinese market working with groups to conduct clinical trials and then
proceeding with SFDA approvals and distribution of products throughout China.�
2011 has been a highly successful year for HealthLinx in Asia with over-budget sales of OvPlex� in Singapore,
excellent progress made with the ongoing 220 patient KFDA study in South Korea, signing a commercial
distribution deal with SCL for South Korea and the pending launch of OvPlex� in other south east Asian